After Hours
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. After-hours trades for Gilead Sciences Inc. (GILD) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $78.17. The Gilead Sciences Inc. has recorded 75,923 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Gilead Emphasizes Unique Ways To Hire Top Talent.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
Stocks Info
Gilead Sciences Inc. is listed on the NASDAQ in the Healthcare sector while operating in the Drug Manufacturers – General industry. At the end of the last regular session, the stock closed at $78.17 and fluctuated between $79.08 as its day high and $77.91 as its day low. The current market capitalization of Gilead Sciences Inc. is $98.17B. A total of 3.52 million shares were traded on the day, compared to an average of 5.48M shares.
Insider Activity
Insider trades are also considered as indicators of how a stock will perform in the future, in addition to stock predictions. During the recent three months, GILD has seen 15 BUY and 8 SELL insider trades, representing the acquisition of 86,990 and the disposition of 54,063 shares. Over the last 12 months, there were 50 BUYs and 38 SELLs from insiders. Insiders purchased 582,642 shares during that period but sold 205,591.
In the most recent transaction, Parsey Merdad sold 6,126 shares of GILD for 78.99 per share on Mar 13. After the transaction, the Chief Medical Officer now owns 70,130 company shares. In a previous transaction on Mar 01, Parsey Merdad sold 12,984 shares at 79.96 per share. GILD shares that Chief Medical Officer owns now total 70,130.
Among the insiders who sold shares, Parsey Merdad disposed of 553 shares on Dec 30 at a per-share price of $85.33. This resulted in the Chief Medical Officer holding 45,556 shares of GILD after the transaction. In another insider transaction, Wilfong Diane E. sold 6,416 shares at $83.50 per share on Nov 09. Company shares held by the SVP, Controller & CAO now total 28,333.
Dividend
The reasons why investors prefer dividend-paying companies are that dividends generate immediate cash flow and indicate that the company will perform well in the future. Gilead Sciences Inc. pays an annual dividend of $3.00, resulting in a dividend yield of 3.84%, and it has a price to earnings (P/E) ratio of 17.67. GILD’s most recent ex-dividend date was 6/14/2023 when it declared a $0.75 quarterly dividend that was paid in cash on 6/29/2023. Previously, the company paid the dividend on 3/30/2023 with an ex-dividend date of 3/14/2023. The GILD stock dividend was $0.75 per share in cash.
Despite rarely being accurate, price targets can exert some form of influence at times, and are often regarded as valuable by markets. According to analysts who have offered 12-month price targets for GILD in the last 3 months, the mean price target is $91.05 with high estimates of $115.00 and low estimates of $77.00. In terms of 52-week highs and lows, GILD has a high of $89.74 and a low of $57.17.
As of this writing, GILD has an earnings estimate of $1.71 per share for the current quarter. EPS was calculated based on a consensus of 22 estimates, with a high estimate of $1.96 per share and a lower estimate of $1.54. The company reported an EPS of $1.67 in the last quarter, which was 12.10% higher than expectations of $1.49.
Balance Sheet Annually/Quarterly
As well as showing the assets and liabilities of the company, the balance sheet also shows the amount invested in equity by investors. Investors can analyze a company’s future prospects by calculating its financial ratios based on this information. GILD’s latest balance sheet shows that the firm has $7.83B in Cash & Short Term Investments as of fiscal 2021. There were $26.70B in debt and $11.61B in liabilities at the time. Its Book Value Per Share was $16.82, while its Total Shareholder’s Equity was $21.06B.
Analysts Opinion
After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for GILD is Buy with a score of 3.89.
